athlete03 said:
What does MDMA do to dopamine?
it raises dopamine levels. in fact it is pro-dopamine and pro-seratonin, more seratonergic than dopaminergic.
the study below deals with trying to determine which has the greater effect, drugs affecting seratonin levels or drugs affecting dopamine levels, on stimulus and reinforcing effects on humans. and from what i can understand of the study, they still don't know if MDMA has a direct effect on dopamine levels, or if it increases as a result of the increase in seratonin (even though seratonin reportedly decreases dopamine levels).
fuck, all i know is that it fucks with dopamine levels.... so there
.
here's the study:
experiments described in this proposal is to increase our understanding of the interaction between
serotonin (5-HT) and dopamine (DA) systems in mediating the subjective, discriminative stimulus, and reinforcing effects of psychostimulant drugs in humans. This proposal will use three primary approaches to study DA/5-HT interactions:
first, a drug with mixed DA/5-HT properties, 3,4- methylenedioxymethamphetamine (MDMA), will be compared to drugs with more selective DA (e.g., d- amphetamine) vs. 5-HT (e.g., d-fenfluramine) mechanisms of action; second, d-amphetamine and d-fenfluramine will be co- administered in such a way as to produce mixed DA/5-HT effects which will be compared to the effects of the compounds administered alone; and third, serotonin- mediated effects will be blocked either by fluoxetine or tryptophan depletion in order to isolate the effects of dopamine with the expectation that this blockade will have differential effects on amphetamine, fenfluramine and MDMA.
Although amphetamine and fenfluramine are similar structurally, they have significantly different subjective, discriminative stimulus and reinforcing effects.
These differences in dependence-related effects are presumably related to the fact that amphetamine produces prominent effects on DA systems whereas fenfluramine´s effects are mediated primarily by 5-HT systems. Interestingly, MDMA, which structurally is an amphetamine derivative, has prominent effects on both 5-HT and DA brain systems but unlike fenfluramine has abuse potential more like that of amphetamine. Thus, MDMA may be a useful compound for investigating the interactions among neurochemical systems as they relate to effects of drugs that are dependence-related. Although most psychostimulants that are abused alter norepinephrine (NE), DA, and to a lesser degree 5-HT levels, there are compelling data that DA systems play the major role in the reinforcing properties and other dependence- related effects of psychostimulant drugs. On the other hand, DA and 5-HT neurochemical systems are known to interact; for instance, recent studies have demonstrated a potentiation of impulse-dependent DA release by 5-HT. MDMA, whose effects have been attributed to its actions on 5-HT systems as well as DA has been shown in animal studies to share discriminative stimulus and reinforcing effects with amphetamine. On the other hand, humans have also reported that it produces hallucinogenic- like effects. Animal brain dialysis studies have shown that pretreatment with selective 5-HT reuptake inhibitors (SSRIs such as fluoxetine, Prozac) will prevent fenfluramine from producing 5-HT release. Similarly, the 5-HT releasing property of MDMA is blocked by pretreatment with the selective SSRIs. The SSRIs provides us with a useful tool for investigating in humans how the dependence related actions of MDMA are modified by manipulations of its effects on 5-HT.
To date, there are no well designed, double-blind studies of MDMA compared with prototypical psychostimulants or 5- HT releasing drugs. Based on animal research and reports of its abuse,
we are hypothesizing that MDMA will resemble d- amphetamine more than d-fenfluramine in terms of its mood- altering properties although it may produce additional hallucinogenic effects. In addition, we hypothesize that MDMA, like amphetamine, will increase motor activity. On the other hand, we hypothesize d-amphetamine and MDMA will differ in a laboratory test of aggression, the point subtraction aggression paradigm, with d-amphetamine at the doses being used increasing aggression and MDMA decreasing it.
To characterize the discriminative stimulus properties of MDMA in recreational drug users. Based upon the results of animal research we are hypothesizing that MDMA will share discriminative properties with d-amphetamine but not d- fenfluramine. Specifically we are hypothesizing that subjects trained to discriminate between placebo, d-amphetamine and d-fenfluramine will respond to MDMA as if it is d- amphetamine. Recreational drug users will be trained to discriminate 10 mg/70 kg d-amphetamine from 30 mg/70 kg d-fenfluramine and placebo and tested with two doses of MDMA (to be determined in pilot study) to evaluate its discriminative properties, i.e., whether it is more amphetamine-like or fenfluramine-like.
To systematically measure the interaction of d- amphetamine and d-fenfluramine in healthy volunteers.
The hypothesis is that increasing 5-HT release by the administration of d-fenfluramine will decrease the subjective stimulant effects of d-amphetamine and d-amphetamine will attenuate the typical aversive subjective effects of d- fenfluramine. A secondary hypothesis is that some of these drug combinations will result in subjective effects that resemble MDMA (mixed stimulant and hallucinogenic effects). Subjects will receive a fixed dose of d-amphetamine (10 mg/70 kg) in combination with a range of d-fenfluramine doses (15 mg/70 kg, 30 mg/70 kg, and placebo). A second group of subjects will receive a fixed dose of d-fenfluramine (15 mg/70 kg) in combination with a range of d-amphetamine doses (10 mg/70 kg, 20 mg/70 kg, and placebo).
To evaluate the effect of pretreatment with fluoxetine on the behavioral and subjective effects of d-amphetamine, d- fenfluramine, and MDMA in recreational drug users. The hypothesis is that fluoxetine, by blocking the 5-HT transporter and thereby preventing the uptake of d- fenfluramine into neurons where it can release 5-HT, will block to a major degree its characteristic subjective effect profile. In contrast, pretreatment with fluoxetine will have only minor effects on the stimulant-like subjective and reinforcing effects of d-amphetamine.
Although it is known that MDMA´s effects on serotonergic neurons can be blocked by fluoxetine, we are hypothesizing that MDMA´s stimulant-like and dependence-producing effects are mediated by DA, and that fluoxetine pretreatment would not significantly attenuate them. However, any of MDMA´s effects which are mediated by 5-HT (e.g., changes in the LSD scale score of the ARCI, changes in the Hallucinogen Rating Scale), will be attenuated. Subjects will be randomized to receive pre-treatment with fluoxetine or placebo. Subjects in both groups will then be tested with single doses of placebo, d-fenfluramine (30 mg/70 kg), d-amphetamine (10 mg/70 kg), and MDMA (dose to be determined) under double-blind, balanced-order conditions. The subjective and reinforcing effects of the MDMA, d- amphetamine, d-fenfluramine and placebo will be compared across groups.
The tryptophan depletion paradigm, which transiently reduces brain 5-HT levels, will be used to investigate the effect of acute reduction in presynaptic 5-HT levels on the subjective and reinforcing properties of d-fenfluramine, d- amphetamine and MDMA. The hypothesis is that tryptophan depletion, but not sham depletion (tryptophan is added back to the amino-acid slurry), will attenuate the characteristic subjective and reinforcing effects of d-fenfluramine and produce only modest attenuation of the stimulant-like effects of d-amphetamine. As in the experiment with fluoxetine, the effects of depletion on MDMA´s effects will be a function of which neurochemical system is mediating its dependence- related effects. We are hypothesizing that depletion of 5-HT will attenuate the hallucinogenic effects of MDMA but have little effect on the stimulant and reinforcing effects of MDMA. Volunteers will be randomly assigned to one of four groups. Each subject will undergo both tryptophan and sham depletion paradigms under double-blind conditions. At the nadir of plasma tryptophan levels, each of the groups will receive either d-amphetamine (10 mg/70 kg), d-fenfluramine (30 mg/70 kg), or MDMA (dose to be determined), or placebo.
In conjunction with the studies outlined above blood samples will be collected for the measurement of homovanillic acid (HVA), the principal metabolite of dopamine, as well as cortisol and prolactin. These measures will provide objective data about the neurochemical and neurohormonal effects of the various drugs alone and in combination. This will allow the correlation of drug induced mood and behavioral changes with the neurochemical and neurohormonal changes mediated by DA and 5-HT. This series of studies will provide novel and scientifically valuable information about the role of DA/5-HT interactions in the subjective, discriminative stimulus, and reinforcing effects of psychostimulant drugs in humans. In addition, these studies will provide objective data on the neurochemical, neurohormonal, subjective and reinforcing effects of MDMA under standardized laboratory conditions.
There is a large, often conflicting literature describing functional 5-HT and DA system interactions both in vitro and in vivo. Some studies report an inhibition of DA systems by 5-HT while others report a 5-HT facilitation of impulse-dependent DA release.
In behavioral paradigms, it appears that increased 5-HT activity does decrease the reinforcing properties of d- amphetamine. For instance, acute administration of the 5-HT precursor L-tryptophan, the 5-HT releasing agent d-fenfluramine, the direct 5-HT agonist quipazine, and the 5-HT reuptake inhibitor fluoxetine decreased the rate of amphetamine self- administration, while chemical 5-HT depletions enhance the rate of responding for amphetamine.
Furthermore, the 5-HT antagonist metergoline enhanced d-amphetamine self- administration, while cyproheptidine and methysergide reduced self-administration frequency.
This inhibitory interaction between 5-HT and DA systems was consistent with a recent drug interaction study in humans in which a mutual antagonism of the mood altering properties of D,L-fenfluramine and phentermine were observed. Interestingly, in a drug discrimination paradigm in rats, this combination was discriminated as more cocaine-like than either drug alone. This points to the importance of studying the interaction of d- amphetamine and fenfluramine in humans.
On the other hand, two studies in cocaine abusing human subjects report the opposite interaction. Satel et al., (1995) and Aronson et al. (1995) reported that tryptophan depletion, a procedure which acutely decreases 5-HT levels in the brain resulted in a decreased subjective response to intranasal administration of cocaine and to decreased cue-induced cocaine craving. Taken together, these different results may be a function of drug (cocaine versus d- amphetamine), different experimental paradigms, different brain regions being examined, different procedures, as well as different species. Nevertheless, this sort of conflicting data speaks to the need to conduct additional research in humans.
d-Amphetamine is a prototypical psychostimulant drug which is used clinically in the treatment of narcolepsy and attention-deficit hyperactivity disorder. In humans it has positive subjective effects, increasing vigor, elation, arousal, and positive mood, is clearly discriminated from caffeine and fenfluramine, but not phenmetrazine, is reinforcing, and has a biphasic response on aggression with low doses increasing aggressive responding and higher doses decreasing the aggressive responses. d-
Fenfluramine is a potent 5-HT releaser and reuptake blocker which has recently been approved by the FDA as a treatment for obesity. Much less research work has been done in humans with this more selective enantiomer than with its racemic (d,l-) form. Although the studies in this proposal will use d-fenfluramine, it is assumed that these effects will be similar to those produced by d,l-fenfluramine. d,l- Fenfluramine has been shown to have mildly aversive subjective effects (increased anxiety and confusion and decreased elation and positive mood scales on the POMS; Brauer et al., 1996), is discriminated from d-amphetamine (Chait et al., 1986), is not reinforcing in humans or rhesus monkeys. Although no clinical data from humans has indicated any long-term problems with fenfluramine, animals studies in rats, guinea pigs, and rhesus monkeys have indicated that there are long- term changes in 5-HT neurons that may even be irreversible in particular brain regions.
The pharmacology of MDMA is well known from animal studies and there have been numerous studies comparing it to prototypic dopaminergic (e.g., amphetamine) and serotonergic (e.g., fenfluramine) drugs.
There is evidence that MDMA is self-administered in monkeys (Beardsley et al., 1986) suggesting human abuse liability. However, there are no well- controlled studies comparing the subjective (reinforcing) or objective (changes in temperature, heart rate or blood pressure) effects of MDMA in human subjects to other drugs, such as d-amphetamine and/or d-fenfluramine (McCann and Ricaurte, 1993; Grob et al., 1992; Liester et al., 1992). The only data that are available are retrospective subjective reports of symptoms experienced following MDMA ingestion (Greer and Talbert 1986; Downing 1986; Peroutka et al., 1988). In these reports, users describe a wide range of subjective effects ranging from "altered time perception" or a sense of "closeness" with other people, increased alertness, luminescence of objects, and decreased "hostility." It is important to note that the MDMA was usually taken in a social context in which people were told what effects they would experience. These expectations may have been of great importance in modulating the subjective experiences produced by MDMA. Common side effects or adverse effects reported by MDMA users include: insomnia, nausea, tight jaw muscles, dry mouth, diaphoresis, trouble concentrating, palpitations, tremor, and increased body temperature. Much less commonly, there are single case reports of liver failure, accidents, and cerebral hemorrhage (see Green et al., 1995 for review). Grob et al., (1996) have recently reported that low doses of MDMA (1 mg/kg) cause robust increases in prolactin and adrenocorticotropin hormone levels compared with placebo.
MDMA has more serotonergic activity than d- amphetamine and like fenfluramine, high doses have been associated with selective damage to serotonergic systems with a sparing of DA systems in rats and non-human primates. Interestingly, in mice, MDMA caused DA not 5-HT neurotoxicity. Moreover, unlike other neurotoxins such as 1- methyl-1,2,3,6-tetrahydropyridine [MPTP] which has been associated with severe depletion of dopamine and clinical symptoms of Parkinson´s disease, there is no clear evidence that MDMA use results in any neurotoxicity in humans. Ricaurte and associates (1990) have reported decreased cerebral spinal fluid 5-HIAA (the primary serotonin metabolite) levels in subjects who had previously taken MDMA (as well as other drugs) although there were no physical or psychological symptoms associated with these changes nor was MDMA use verified or the potential influence of others factors controlled.
The mechanism by which [MDMA] exerts its unique effects in humans is not well understood and cannot be reliably extrapolated from the animal literature or retrospective reports in humans. The studies in this application are designed to provide important information about the effects of MDMA in humans. In the proposed studies, several subjective (Johanson and Uhlenhuth, 1980) and behavioral measures will be used to compare across drugs. In addition to standard subjective effects, the discriminative stimulus effects of amphetamine, fenfluramine, and MDMA will be compared. Drug discrimination procedures provide a powerful technique to classify and differentiate closely related compounds and provide important information concerning their mechanisms of action.
MDMA is discriminated as amphetamine in d-amphetamine trained rats, pigeons, and rhesus monkeys, but also as fenfluramine in fenfluramine-trained rats. In rats trained to discriminate MDMA, d- amphetamine did not substitute for MDMA, while fenfluramine partially substituted. Evans, et al. (1990), showed in a three-way discrimination (amphetamine, fenfluramine, placebo) in pigeons that MDMA had both amphetamine-like and fenfluramine-like effects with differences across individuals and across doses. This study is being conducted in "recreational drug users." Individuals who have tried drugs of abuse but have not developed drug abuse problems are ideal from an ethical viewpoint since their failure to become drug abusers, even though they have passed through the age of risk for severe drug dependence (Anthony et al., 1994; Breslau et al., 1993) and have sampled some drugs of abuse, means that exposure to amphetamine in a laboratory study would be an insignificant risk factor. Amphetamine and fenfluramine are therapeutic drugs and are frequently given to naive patients as part of outpatient therapy with little evidence of iatrogenic dependence (Schuster, 1989). Finally, d-amphetamine in the 10 mg/70 kg to 35 mg/70 kg dose proposed in the present have been given to normal volunteers in previous studies with no reports of serious adverse reactions.
In addition to comparison studies using subjective, discriminative stimulus, and reinforcing effects, drug interaction studies may help elucidate the mechanism of action mediating various subjective, behavioral and physiological effects of drugs. In the present studies, 5-HT systems are being manipulated by acute treatments with fluoxetine (5-HT transporter inhibitor) and with tryptophan depletion. These studies, will provide important information regarding which effects of MDMA and d-amphetamine are mediated by serotonin. It might be expected for example that the activity increasing effects of MDMA would be unaffected by manipulations which decrease serotonin activity whereas any hallucinogenic effects of MDMA would be attenuated.¥ 
Please Scroll Down to See Forums Below 
:alien
